Literature DB >> 12004007

Conventional and molecular cytogenetic characterization of a new human cell line, GIST-T1, established from gastrointestinal stromal tumor.

Takahiro Taguchi1, Hiroshi Sonobe, Shin-ichi Toyonaga, Ichiro Yamasaki, Taro Shuin, Atsushi Takano, Keijiro Araki, Kunihiro Akimaru, Kazunari Yuri.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12004007     DOI： 10.1038/labinvest.3780461

Source DB:  PubMed          Journal:  Lab Invest        ISSN： 0023-6837            Impact factor:   5.662


× No keyword cloud information.
  84 in total

1.  Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors.

Authors:  Michael C Heinrich; Adrian Marino-Enriquez; Ajia Presnell; Rachel S Donsky; Diana J Griffith; Arin McKinley; Janice Patterson; Takahiro Taguchi; Cher-Wei Liang; Jonathan A Fletcher
Journal:  Mol Cancer Ther       Date:  2012-06-04       Impact factor: 6.261

2.  Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors.

Authors:  Noah A Cohen; Shan Zeng; Adrian M Seifert; Teresa S Kim; Eric C Sorenson; Jonathan B Greer; Michael J Beckman; Juan A Santamaria-Barria; Megan H Crawley; Benjamin L Green; Ferdinand Rossi; Peter Besmer; Cristina R Antonescu; Ronald P DeMatteo
Journal:  Cancer Res       Date:  2015-04-02       Impact factor: 12.701

3.  SOCS1 gene therapy has antitumor effects in imatinib-resistant gastrointestinal stromal tumor cells through FAK/PI3 K signaling.

Authors:  Takahito Sugase; Tsuyoshi Takahashi; Satoshi Serada; Minoru Fujimoto; Tomoharu Ohkawara; Kosuke Hiramatsu; Toshirou Nishida; Seiichi Hirota; Yurina Saito; Koji Tanaka; Yasuhiro Miyazaki; Tomoki Makino; Yukinori Kurokawa; Makoto Yamasaki; Kiyokazu Nakajima; Kazuhiro Hanasaki; Tadamitsu Kishimoto; Masaki Mori; Yuichiro Doki; Tetsuji Naka
Journal:  Gastric Cancer       Date:  2018-04-05       Impact factor: 7.370

4.  Evaluating new therapies in gastrointestinal stromal tumor using in vivo molecular optical imaging.

Authors:  Harvey Hensley; Karthik Devarajan; James R Johnson; David Piwnica-Worms; Andrew K Godwin; Margaret von Mehren; Lori Rink
Journal:  Cancer Biol Ther       Date:  2014-04-22       Impact factor: 4.742

5.  Platelet-Derived Growth Factor Receptor-α Regulates Proliferation of Gastrointestinal Stromal Tumor Cells With Mutations in KIT by Stabilizing ETV1.

Authors:  Yujiro Hayashi; Michael R Bardsley; Yoshitaka Toyomasu; Srdjan Milosavljevic; Gabriella B Gajdos; Kyoung Moo Choi; K Marie Reid-Lombardo; Michael L Kendrick; Juliane Bingener-Casey; Chih-Min Tang; Jason K Sicklick; Simon J Gibbons; Gianrico Farrugia; Takahiro Taguchi; Anu Gupta; Brian P Rubin; Jonathan A Fletcher; Abhijit Ramachandran; Tamas Ordog
Journal:  Gastroenterology       Date:  2015-04-09       Impact factor: 22.682

6.  A unique model for SDH-deficient GIST: an endocrine-related cancer.

Authors:  James F Powers; Brent Cochran; James D Baleja; Hadley D Sikes; Xue Zhang; Inna Lomakin; Troy Langford; Kassi Taylor Stein; Arthur S Tischler
Journal:  Endocr Relat Cancer       Date:  2018-07-02       Impact factor: 5.678

7.  Increased KIT inhibition enhances therapeutic efficacy in gastrointestinal stromal tumor.

Authors:  Teresa S Kim; Michael J Cavnar; Noah A Cohen; Eric C Sorenson; Jonathan B Greer; Adrian M Seifert; Megan H Crawley; Benjamin L Green; Rachel Popow; Nagavarakishore Pillarsetty; Darren R Veach; Anson T Ku; Ferdinand Rossi; Peter Besmer; Cristina R Antonescu; Shan Zeng; Ronald P Dematteo
Journal:  Clin Cancer Res       Date:  2014-02-28       Impact factor: 12.531

8.  Genome-wide functional screening identifies CDC37 as a crucial HSP90-cofactor for KIT oncogenic expression in gastrointestinal stromal tumors.

Authors:  A Mariño-Enríquez; W-B Ou; G Cowley; B Luo; A H Jonker; M Mayeda; M Okamoto; G Eilers; J T Czaplinski; E Sicinska; Y Wang; T Taguchi; G D Demetri; D E Root; J A Fletcher
Journal:  Oncogene       Date:  2013-04-15       Impact factor: 9.867

9.  Detection of treatment-induced changes in signaling pathways in gastrointestinal stromal tumors using transcriptomic data.

Authors:  Michael F Ochs; Lori Rink; Chi Tarn; Sarah Mburu; Takahiro Taguchi; Burton Eisenberg; Andrew K Godwin
Journal:  Cancer Res       Date:  2009-11-10       Impact factor: 12.701

10.  Insulin-like growth factor binding protein-3 has dual effects on gastrointestinal stromal tumor cell viability and sensitivity to the anti-tumor effects of imatinib mesylate in vitro.

Authors:  Jheri J Dupart; Jonathan C Trent; Ho-Young Lee; Kenneth R Hess; Andrew K Godwin; Takahiro Taguchi; Wei Zhang
Journal:  Mol Cancer       Date:  2009-11-10       Impact factor: 27.401
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.